查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1938206

類風濕性關節炎藥物市場－全球產業規模、佔有率、趨勢、機會及預測（依分子類型、藥物類別、通路、地區及競爭格局分類，2021-2031年）

Rheumatoid Arthritis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type of Molecule, By Drug Class, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球類風濕性關節炎治療市場預計將從 2025 年的 597.1 億美元成長到 2031 年的 855.2 億美元，複合年成長率為 6.17%。

該類藥物包括非類固醇消炎劑、皮質類固醇和緩解疾病抗風濕藥，所有這些藥物都旨在抑制免疫介導的發炎並保護關節結構。全球人口老化和自體免疫疾病發生率上升是推動市場成長的主要因素，因為這些疾病需要長期持續的藥物治療。此外，診斷技術的進步使得疾病的早期發現成為可能，從而有效增加了符合治療性介入的患者數量。

市場概覽
預測期 2027-2031
市場規模：2025年 597.1億美元
市場規模：2031年 855.2億美元
複合年成長率：2026-2031年 6.17%
成長最快的細分市場 製藥
最大的市場 北美洲

然而，生物製劑的高成本給該行業帶來了許多挑戰，生物製藥，導致低成本生物相似藥進入市場，蠶食了部分市場佔有率。風濕性疾病負擔之重凸顯了有效管理風濕性疾病的迫切性。根據美國關節炎基金會預測，到2025年，美國將有約6,000萬成年人被診斷出患有某種類型的關節炎，凸顯了製定強力的治療策略的迫切需求。

市場促進因素

推動市場成長的關鍵因素之一是生物製藥和標靶合成緩解疾病抗風濕藥物（DMARDs）的日益普及，因為醫療服務提供者正在尋求比傳統治療方法緩解率更高的治療方案。醫生擴大選擇具有創新作用機制的藥物，例如JAK抑制劑，這類藥物能夠快速緩解症狀並預防關節結構損傷。這種追求高品質、高效療法的趨勢也反映在財務表現上。根據艾伯維公司於2025年10月發布的“2025年第三季財務業績”，JAK抑制劑RINVOQ的全球淨銷售額飆升至21.84億美元，增幅達35.3%，這主要得益於銷量和市場佔有率的成長。這顯示臨床上對標靶治療有著強烈的偏好。

同時，全球人口快速老化也成為持續的市場驅動力，因為老年人更容易罹患與類風濕性關節炎相關的自體免疫疾病。這種人口結構的變化需要製定長期管理策略，並顯著增加藥物消耗。根據2025年4月發表在《免疫學前沿》（Frontiers in Immunology）上的一份報告，全球老年人類風濕性關節炎的盛行率估計為790萬例，凸顯了對可擴展老年護理日益成長的需求。為了控制不斷成長的患者群體所帶來的成本，醫療保健系統正在轉向更具成本效益的解決方案。正如Evernorth Health Services在2025年8月指出的那樣，從2024年底到2025年初，發炎性疾病的生物相似藥索賠增加了46.5%，這表明治療選擇正朝著更容易取得的方向發展。

市場挑戰

生物製藥的高昂成本，加上關鍵藥物專利到期以及隨之而來的生物類似藥湧入，為類風濕性關節炎領域的收入成長帶來了巨大障礙。生物製藥通常定價較高，加重了醫療預算的負擔，並阻礙了其在財政資源有限地區的市場滲透。隨著這些重磅藥物的專利保護期結束，價格更低廉的生物相似藥迅速進入市場，加劇了競爭，迫使原廠藥公司降價或放棄市場佔有率。雖然這種動態可能增加接受治療的患者數量，但往往會縮小市場的整體價值。

近期產業數據顯示，生物相似藥的成本效益提升，也印證了收入下降的影響。根據美國可及藥品協會（Association for Accessible Medicines）預測，到2025年，生物相似藥的使用將為美國醫療保健系統每年節省202億美元。這筆巨額收入其實已從品牌藥市場消失。因此，儘管價格更低廉的替代藥物的普及提高了患者獲得治療的機會，但也直接阻礙了全球類風濕性關節炎治療藥物市場的成長，因為利潤率高的原研藥銷售被利潤率較低的學名藥和生物類似藥銷售所取代。

市場趨勢

基於生物標記的精準醫療正在變革治療策略，使其從試驗處方模式轉向基於分子譜的個人化醫療。這項轉變滿足了早期識別對昂貴生物製藥無反應患者的迫切需求，從而最佳化臨床療效並減少經濟浪費。 Cipher Medicine公司於2025年6月宣布了一項重要的進展。該公司宣布，他們利用人工智慧驅動的演算法分析了約1500名類風濕性關節炎患者的真實臨床數據，並識別出能夠準確預測治療成功的臨床指標。此類創新使醫生能夠選擇最適合每位患者獨特生物學特徵的作用機制，從而實現超越常規治療指南的治療方案。

同時，將數位健康工具整合到醫療服務中，以增強即時症狀監測並提高用藥依從性，已成為強勁的趨勢。隨著疾病管理越來越依賴複雜的自我管理療法，行動應用程式對於彌合醫療諮詢與日常自我護理之間的鴻溝至關重要。然而，維持長期、持續的參與度仍然是一個挑戰。 2025年12月發表在《風濕病國際》（Rheumatology International）上的一項研究調查了2036名成年用戶，發現只有25.8%的用戶達到了12週的持續遵從性標準。這項發現印證了業界致力於開發更直覺、以患者為中心的數位平台，以確保處方療法的全部臨床益處能夠透過持續使用得以實現。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球類風濕性關節炎治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依分子類型（藥品、生物藥品）
    • 依藥物類別（非類固醇消炎劑（NSAIDs）、緩解疾病抗風濕藥（DMARDs）、皮質類固醇、鎮痛藥、其他）
    • 通路（處方藥、非處方藥）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美類風濕性關節炎藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲類風濕性關節炎藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區類風濕性關節炎藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲類風濕性關節炎藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美類風濕性關節炎藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球類風濕性關節炎藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17264

The Global Rheumatoid Arthritis Drugs Market is projected to expand from USD 59.71 Billion in 2025 to USD 85.52 Billion by 2031, reflecting a compound annual growth rate of 6.17%. This pharmaceutical sector encompasses nonsteroidal anti-inflammatory drugs, corticosteroids, and disease-modifying antirheumatic drugs, all designed to suppress immune-mediated inflammation and protect joint structure. Market growth is fundamentally supported by an aging global population and the rising incidence of autoimmune disorders, which demand consistent, long-term pharmacological management. Furthermore, advancements in diagnostic technologies are enabling earlier detection of the disease, effectively increasing the number of patients eligible for therapeutic intervention.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 59.71 Billion
Market Size 2031USD 85.52 Billion
CAGR 2026-20316.17%
Fastest Growing SegmentPharmaceuticals
Largest MarketNorth America

Conversely, the industry faces substantial hurdles due to the high cost of biologic therapies, which limits accessibility in price-sensitive regions and places a strain on healthcare budgets. This difficulty is compounded by the expiration of patents for major biologic agents, resulting in market erosion as lower-cost biosimilars become available. The urgency for effective rheumatic disease management is highlighted by the sheer burden of the condition; according to the Arthritis Foundation, approximately 60 million adults in the United States were reported to be living with doctor-diagnosed arthritis in 2025, underscoring the critical need for robust treatment strategies.

Market Driver

A primary catalyst for market expansion is the growing adoption of biologics and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), as healthcare providers seek therapies with superior remission rates compared to traditional options. Physicians are increasingly favoring agents with innovative mechanisms of action, such as JAK inhibitors, which offer rapid symptom relief and prevent structural joint damage. This trend toward premium, high-efficacy therapeutics is reflected in financial performance; according to AbbVie's 'Third-Quarter 2025 Financial Results' from October 2025, global net revenues for the JAK inhibitor Rinvoq surged to $2.184 billion, a 35.3% increase driven by volume growth and market share gains, demonstrating a strong clinical preference for targeted interventions.

Simultaneously, the rapidly aging global population acts as a sustained driver for the market, given the elderly's heightened susceptibility to the autoimmune dysregulation associated with rheumatoid arthritis. This demographic shift requires long-term management strategies, significantly boosting the consumption of therapeutic agents. As reported by Frontiers in Immunology in April 2025, the global prevalence of rheumatoid arthritis among the elderly was estimated at 7.9 million cases, emphasizing the growing need for scalable geriatric care. To manage the costs associated with this expanding patient base, systems are turning to cost-effective solutions; Evernorth Health Services noted in August 2025 that biosimilar claims for inflammatory conditions rose by 46.5% between late 2024 and early 2025, indicating a pivot toward accessible treatment options.

Market Challenge

The substantial cost of biologic therapies, combined with the patent expiration of key drugs and the subsequent influx of biosimilars, creates a significant barrier to revenue growth in the rheumatoid arthritis sector. Biologics typically carry premium price tags, which burden healthcare budgets and restrict market penetration in regions with limited financial resources. As exclusivity protections for these blockbuster drugs lapse, affordable biosimilars rapidly enter the market, intensifying competition and compelling originator companies to lower prices or cede market share. This dynamic leads to a contraction in overall market value, even as the volume of patients receiving treatment may increase.

The impact of this revenue erosion is confirmed by recent industry data regarding cost savings. According to the Association for Accessible Medicines, the utilization of biosimilar medicines in 2025 generated $20.2 billion in savings for the U.S. healthcare system over the prior year. This figure represents a substantial amount of revenue effectively removed from the branded pharmaceutical market. Consequently, while the availability of cheaper alternatives improves patient access to care, it directly hinders the financial expansion of the Global Rheumatoid Arthritis Drugs Market by replacing high-margin therapeutic revenue with lower-value generic and biosimilar sales.

Market Trends

The integration of biomarker-driven precision medicine is transforming therapeutic strategies, moving the field from trial-and-error prescription models toward personalized care based on molecular profiles. This shift addresses the critical need to identify non-responders to expensive biologics at an early stage, thereby optimizing clinical outcomes and reducing financial waste. A significant step in this direction was highlighted by Scipher Medicine in June 2025, when they announced that an AI-driven algorithm had analyzed real-world data from nearly 1,500 rheumatoid arthritis patients to identify clinical measures that accurately predict therapy success. Such innovations allow physicians to choose the most effective mechanism of action for a patient's unique biology, advancing beyond generalized treatment guidelines.

Concurrently, there is a strong trend toward integrating digital health tools designed to enhance real-time symptom monitoring and improve medication adherence. As disease management increasingly depends on complex self-administered regimens, mobile applications are becoming essential for bridging the gap between clinical appointments and daily self-care, although sustaining long-term engagement remains a challenge. A study published in Rheumatology International in December 2025 evaluated 2,036 adult users and found that only 25.8% met the criteria for sustained adherence over a 12-week period. This finding underscores the industry's growing focus on developing more intuitive, patient-centric digital platforms to ensure that the clinical benefits of prescribed therapies are fully realized through consistent usage.

Key Market Players

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG

Report Scope

In this report, the Global Rheumatoid Arthritis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rheumatoid Arthritis Drugs Market, By Type of Molecule

  • Pharmaceuticals
  • Biopharmaceuticals

Rheumatoid Arthritis Drugs Market, By Drug Class

  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • disease-modifying antirheumatic drugs (DMARDs)
  • Corticosteroids
  • Analgesics
  • Other

Rheumatoid Arthritis Drugs Market, By Distribution Channel

  • Prescription
  • Over the counter (OTC)

Rheumatoid Arthritis Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rheumatoid Arthritis Drugs Market.

Available Customizations:

Global Rheumatoid Arthritis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rheumatoid Arthritis Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type of Molecule (Pharmaceuticals, Biopharmaceuticals)
    • 5.2.2. By Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), Corticosteroids, Analgesics, Other)
    • 5.2.3. By Distribution Channel (Prescription, Over the counter (OTC))
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Rheumatoid Arthritis Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Molecule
    • 6.2.2. By Drug Class
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Rheumatoid Arthritis Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type of Molecule
        • 6.3.1.2.2. By Drug Class
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Rheumatoid Arthritis Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type of Molecule
        • 6.3.2.2.2. By Drug Class
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Rheumatoid Arthritis Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type of Molecule
        • 6.3.3.2.2. By Drug Class
        • 6.3.3.2.3. By Distribution Channel

7. Europe Rheumatoid Arthritis Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Molecule
    • 7.2.2. By Drug Class
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Rheumatoid Arthritis Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type of Molecule
        • 7.3.1.2.2. By Drug Class
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Rheumatoid Arthritis Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type of Molecule
        • 7.3.2.2.2. By Drug Class
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Rheumatoid Arthritis Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type of Molecule
        • 7.3.3.2.2. By Drug Class
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Rheumatoid Arthritis Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type of Molecule
        • 7.3.4.2.2. By Drug Class
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Rheumatoid Arthritis Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type of Molecule
        • 7.3.5.2.2. By Drug Class
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Rheumatoid Arthritis Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Molecule
    • 8.2.2. By Drug Class
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Rheumatoid Arthritis Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type of Molecule
        • 8.3.1.2.2. By Drug Class
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Rheumatoid Arthritis Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type of Molecule
        • 8.3.2.2.2. By Drug Class
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Rheumatoid Arthritis Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type of Molecule
        • 8.3.3.2.2. By Drug Class
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Rheumatoid Arthritis Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type of Molecule
        • 8.3.4.2.2. By Drug Class
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Rheumatoid Arthritis Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type of Molecule
        • 8.3.5.2.2. By Drug Class
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Rheumatoid Arthritis Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Molecule
    • 9.2.2. By Drug Class
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Rheumatoid Arthritis Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type of Molecule
        • 9.3.1.2.2. By Drug Class
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Rheumatoid Arthritis Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type of Molecule
        • 9.3.2.2.2. By Drug Class
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Rheumatoid Arthritis Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type of Molecule
        • 9.3.3.2.2. By Drug Class
        • 9.3.3.2.3. By Distribution Channel

10. South America Rheumatoid Arthritis Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Molecule
    • 10.2.2. By Drug Class
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Rheumatoid Arthritis Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type of Molecule
        • 10.3.1.2.2. By Drug Class
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Rheumatoid Arthritis Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type of Molecule
        • 10.3.2.2.2. By Drug Class
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Rheumatoid Arthritis Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type of Molecule
        • 10.3.3.2.2. By Drug Class
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Rheumatoid Arthritis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen Inc.
  • 15.3. Bayer AG
  • 15.4. Boehringer Ingelheim GmbH
  • 15.5. Bristol-Myers Squibb Company
  • 15.6. Celgene Corporation
  • 15.7. F. Hoffmann-La Roche AG
  • 15.8. Johnson & Johnson
  • 15.9. Merck & Co. Inc.
  • 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer